Sanfilippo Disease

Barik KL1, Kumar P2, Ghosh TN3, De S4, Basu S5

1Dr. Kanai Lal Barik, MBBS, DCH, MD Associate Professor, 2Dr. Prabhat Kumar, MBBS, MDPG Trainee, 3Dr. Tarak Nath Ghosh, MBBS, MD, Associate Professor, 4Dr. Sangita De, MBBS, PG Trainee, 5Dr. Samit Basu, MBBS, MDPG Trainee. All from Department of Paediatrics, Burdwan Medical Hospital, Burdwan, India.

Address for correspondence: Dr. Prabhat Kumar, Email: prabhatbmch@gmail.com

Abstract
Sanfilippo disease is a type of Mucopolysaccharidosis, a hereditary progressive disease caused by mutation of gene for degradation of acid mucopolysaccharides. Early detection of this rare disease would enable screening and genetic counseling for asymptomatic family members.

Key word: Sanfilippo, Mucopolysaccharides

Introduction
Sanfilippo disease (MPS 3) is a genetically heterogeneous but clinically similar group of 4 recognised types, each type is caused by a different enzyme deficiency involved in the degradation of heparin sulfate. Here a 6 yr male child presented with hearing loss and abnormal behavior. On detailed work up it is nothing but a rare disease. In India it is a rare disease. Sanfilippo is diagnosed based on clinical features, radiographic results, urinary GAG screening test and finally definite diagnosis by Enzyme assay.

The Case
A six years male child presented with bilateral profound hearing loss, delayed milestones and abnormal behavior since the last four years. His developmental milestones up to two years of age was normal. Parents noticed gradual hearing loss, abnormal behavior also gradually increased and he lost acquired skills, visited different doctors and finally arrived to our OPD. There was no motor delay, no other family members had similar problem.

Patient was hyperactive, having aggressive destructive behavior, temper tantrum and sleep disorder.

On examination-Facial abnormality were present; Dolichocephaly, depressed nasal bridge, broad nose, coarse hair, hirsutism. Anthropometry-wt 20 kg, ht-108 cm, Upper to Lower segment Ratio being 1.05, Head circumference was 50 cm and Chest circumference was 61 cm.

BERA done shows profound hearing loss, I.Q <75 (below average), CT brain cortical atrophy with prominent cortical sulci and basal cistern, thyroid profile normal, and on fundoscopy there was no corneal clouding.

Table 1: Various Radiological Findings.

<table>
<thead>
<tr>
<th>X-Ray</th>
<th>Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skull</td>
<td>Hyperostotic calvaria</td>
</tr>
<tr>
<td>Wrist</td>
<td>Proximal pointing of metacarpals with bullet shaped phalanges,</td>
</tr>
<tr>
<td>Chest</td>
<td>Thickened medial 3rd of clavicle with spatulaed ribs, ovoid vertebral body</td>
</tr>
<tr>
<td>Hip</td>
<td>Shallow acetabulum with flaring of ilius</td>
</tr>
</tbody>
</table>

Provisional diagnosis as MPS was kept in mind so urine for GAG was done which came positive. Definite diagnosis was done by enzyme assay; it confirmed Sanfilippo A.
Sanfilippo syndrome, or Mucopolysaccharidosis III (MPS-III) is a rare autosomal recessive lysosomal storage disease. It is caused by a deficiency in one of the enzymes needed to break down the glycosaminoglycan 'heparan sulfate' (which is found in the extra-cellular matrix and on cell surface glycoprotein).

The four types of MPS-III are due to specific enzyme deficiencies affecting the breakdown of heparan sulfate, which then builds up in various organs. MPS-III A, B, C and D are considered to be clinically indistinguishable, although mutations in different genes are responsible for each disease.

The disease manifests in young children. Affected infants are apparently normal, although some mild facial dysmorphism may be noticeable. The stiff joints, hirsuteness and coarse hair typical of other mucopolysaccharidoses are usually not present until late in the disease. After an initial symptom-free interval, patients usually present with a slowing of development and/or behavioral problems, followed by progressive intellectual decline resulting in severe dementia and progressive motor disease. Acquisition of speech is often slow and incomplete. The disease progresses to increasing behavioral disturbance including temper tantrums, hyperactivity, destructiveness, aggressive behaviour, pica and sleep disturbance. As affected children have normal muscle strength and mobility, the behavioral disturbances are very difficult to manage.

The disordered sleep in particular presents a significant problem to care providers. In the final phase of the illness, children become increasingly immobile and unresponsive, often require wheelchairs, and develop swallowing difficulties and seizures. The life-span of an affected child does not usually extend beyond late teens to early twenties.

Although the clinical features of the disease are mainly neurological, patients may also develop diarrhea, carious teeth, and an enlarged liver and spleen.

Of all the MPS diseases, MPS III produces the mildest physical abnormalities. It is important, however, that simple and treatable conditions such as ear infections and toothaches not be overlooked because of behavior problems that make examination difficult. Children with MPS III often have an increased tolerance of pain. Bumps and bruises or ear infections that would be painful for other children often go unnoticed in children with MPS III. Parents may need to search for a doctor with the patience and interest in treating a child with a long-term illness. Some children with MPS III may have a blood-clotting problem during and after surgery. The diagnosis may be confirmed by assay of enzyme levels in tissue samples and gene sequencing. Prenatal diagnosis is possible.

Treatment remains largely supportive. The behavioral disturbances of MPS-III respond poorly to medication. If an early diagnosis is made, bone marrow replacement may be beneficial.
Along with many other lysosomal storage diseases, MPS-III exists as a model of a monogenetic disease involving the central nervous system. Several promising therapies are in development. Gene therapy is under investigation for MPS-III in animal models. Other potential therapies include chemical modification of deficient enzymes to allow them to penetrate the blood-brain barrier, stabilization of abnormal but active enzyme to prevent its degradation, and implantation of stem cells strongly expressing the missing enzyme. For any future treatment to be successful, it must be administered as early as possible. Currently MPS-III is mainly diagnosed clinically, by which stage it is probably too late for any treatment to be very effective. Neonatal screening programs would provide the earliest possible diagnosis.

Conclusion

Early detection of this rare disease would enable screening and genetic counseling for asymptomatic family members. In future by gene therapy it is possible to produce enzyme which help in patients suffering from this disease.

References


How to cite this article?